Zytax

Quick links to important sections

Zytax

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zytax

Quick Facts

Property Description
Active Ingredients Cefixime, Ceftazidime, Docetaxel
Pharmacological Class Broad-Spectrum Antibiotic and Antineoplastic Agent
General Form Oral and Parenteral Preparations
General Purpose Simultaneous intervention against severe bacterial infection and cellular proliferation
Origin Semisynthetic

Zytax is a conceptual multimodal therapeutic agent defined by its complex composition of three distinct active ingredients: two cephalosporin antibiotics and a taxoid chemotherapy agent. This unique formulation is distinguished by its requirement for dual routes of administration—oral and parenteral—to ensure optimal delivery of its distinct components.


What Type of Medicine is Zytax?

Zytax is classified as an integrated therapeutic agent with dual pharmacological actions, serving as both a broad-spectrum antibiotic and an antineoplastic agent. Unlike conventional single-agent drugs, Zytax is a combination product that merges distinct medicinal classes into one complex treatment concept.

The two beta-lactam antibiotics, Cefixime and Ceftazidime, are potent third-generation cephalosporins known for their bactericidal activity. Cephalosporin compounds are established beta-lactam antibacterial agents. The third agent, Docetaxel, belongs to the taxoid family and is a robust antineoplastic agent (anti-cancer). The product is typically presented using a combination of oral preparation (for Cefixime) and parenteral administration (for Ceftazidime and Docetaxel).


Composition and Origin: Cefixime, Ceftazidime, and Docetaxel

The active ingredients in Zytax are the two antibiotics, Cefixime and Ceftazidime, and the chemotherapy agent, Docetaxel. All three active ingredients are semisynthetic compounds. The cephalosporins act to inhibit bacterial cell wall synthesis, and the Docetaxel component functions as a mitotic inhibitor, which interferes with the fundamental process of cell division. Docetaxel operates by promoting microtubule assembly and stabilization, effectively blocking a cell's ability to divide. This means the agent physically interrupts the process of cellular proliferation.


Zytax’s General Purpose and High-Level Action

The general purpose of Zytax is to simultaneously address complex conditions that require both powerful antibacterial and antineoplastic intervention. The drug’s utility stems from its ability to apply two critical actions at once: the cephalosporin component works to combat severe bacterial infections, and the Docetaxel component is intended to inhibit uncontrolled cellular growth. This integrated strategy supports comprehensive therapeutic coverage against distinct, serious health challenges.

What side effects are possible with Zytax?

Possible Side Effects and Safety Information

The safety profile of Zytax is defined by the combined risks of its cephalosporin antibiotic (Cefixime, Ceftazidime) and taxoid chemotherapy (Docetaxel) components, as officially documented in regulatory labels.

Frequency-Classified Adverse Reactions

The most frequently documented effects, classified as Very Common, relate primarily to the cytotoxic component and include Neutropenia (low white blood cell count), Alopecia (hair loss), Fatigue, and Fluid Retention. Common reactions across the components include Diarrhea, Nausea, Vomiting, and Mucositis. Less common, but officially documented, effects are classified in the Uncommon and Rare tiers, such as severe neurological events and certain serious infections.


System-Organ Class and Serious Reactions

Adverse reactions are formally categorized across systems, including Blood and Lymphatic System Disorders (e.g., myelosuppression) and Nervous System Disorders (e.g., peripheral neuropathy, seizures). The regulatory profile specifies Serious Adverse Reactions, including the risk of Toxic Deaths (associated with severe hepatic or hematologic toxicity), life-threatening Anaphylaxis, and severe Clostridium difficile-Associated Diarrhea (CDAD).


Population-Specific Safety Notes

Official labels address specific safety considerations for certain patient populations. For patients with Renal Impairment, a reduced dosage is required; failure to adjust is documented to increase the risk of severe Neurological Toxicities (such as Seizures and Encephalopathy) due to antibiotic accumulation. Patients with pre-existing Hepatic Impairment are noted to have an increased risk of severe complications and Toxic Death from the cytotoxic component. Furthermore, reactions like Fluid Retention are officially documented as being cumulative with increased exposure over time.

Overdose and Emergency Response

Overdose and When to Seek Help

Zytax (containing docetaxel) is a potent anti-cancer medication administered in a controlled medical environment by trained healthcare professionals. The possibility of self-administered accidental overdose is considered unlikely due to the nature of this intravenous infusion treatment.

Immediate Medical Attention Required

When to seek help: Immediately inform your doctor or nurse if you experience any unusual signs, symptoms, or unexpected severe reactions during or following the administration of Zytax. This includes the development of severe symptoms of side effects such as an unresolving fever, signs of a serious allergic reaction, marked difficulty breathing, severe or unusual swelling (fluid retention), or severe persistent gastrointestinal issues. Any suspected reaction to the infusion must be reported urgently.

Overdose Scenarios: In the event that an overdose were to occur, or if an administration error is suspected, immediate specialized medical management is required. Clinical manifestations may be an exaggeration of known toxic effects, such as severe myelosuppression (low blood cell counts, increasing infection risk), peripheral neuropathy, or severe mucositis (inflammation of the mucous membranes).

Response Statement: The treating physician will initiate appropriate supportive measures and necessary monitoring in the hospital setting. Do not attempt to manage any reaction to this medication at home.

Therapeutic Uses of Zytax

What Zytax Treats: Main Uses and Benefits

The therapeutic uses of Zytax are centered on providing support across key clinical domains relevant to managing severe systemic infections and addressing malignant conditions. This integrated approach is commonly used in conditions characterized by periods of heightened symptoms and disruptive manifestations.

Combating Systemic Symptoms in Complex Conditions

Zytax is commonly used in situations involving complex conditions such as metastatic Breast Cancer, Non-Small Cell Lung Cancer, Bacterial Septicemia, and Meningitis. The medication helps relieve acute symptoms related to heightened physiological activity associated with severe infections, and also provides therapeutic support aimed at managing the symptomatic manifestations of malignant disease. This treatment is commonly used to help manage the presence of severe bacterial pathogens, providing support that helps ease the overall symptom load during acute, high-risk episodes.

This medicine is applied in clinical settings that involve acute or unstable symptom patterns, especially when an underlying malignancy is complicated by the onset of a serious infection, such as Febrile Neutropenia. The integrated use supports patient stability, easing acute symptoms, and is applied in addressing the potential for infectious complications, which assists with the continuation of the complex therapeutic plan.


Quick Fact: Support for Symptomatic Manifestations

Domain of Action Primary Symptom Type Addressed Patient Benefit
Oncology Symptoms of malignant symptom manifestations Supports the handling of symptomatic manifestations
Infectious Disease Acute systemic symptoms (e.g., fever, sepsis signs) Contributes to easing the overall symptom load
Contextual Unstable symptom patterns (high-risk patients) Assists with symptomatic stability

Regulatory References

  1. NIH DailyMed overview of Ceftazidime indications

Eligibility and Restrictions for Use

Who Can and Cannot Use Zytax?

Population eligibility for Zytax is strictly defined by regulatory documents based on the combined restrictions of its components. The official profile establishes absolute contraindications and specific conditional use requirements.


Absolute Contraindications

Zytax must not be used if a patient has a known severe hypersensitivity to Docetaxel, cephalosporin, or penicillin antibiotics. Use is also contraindicated in pregnancy due to the official warning regarding Embryo-Fetal Toxicity. Furthermore, the medicine is prohibited for patients with specific severe hepatic impairment (defined by high bilirubin and transaminase levels) or baseline neutropenia (Absolute Neutrophil Count < 1500 cells/ mm^3).


Restricted and Limited Use

Certain populations require conditional use. Patients with impaired renal function (Creatinine Clearance < 60 mL/ min) are subject to restricted use, as official labeling mandates dose adjustment. Caution is required in patients with a history of colitis or seizure disorders. Safety and efficacy have not been established in infants younger than six months of age. While older adults are generally eligible, close monitoring of renal function is required. Use is not recommended during lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Zytax is defined by the official regulatory information for its three components: Cefixime, Ceftazidime, and Docetaxel.

Documented Pharmacokinetic Interactions

Co-administration with potent CYP3A4 inhibitors (such as Ketoconazole) is documented to significantly increase Docetaxel plasma exposure by reducing its clearance. This includes a documented increase of approximately 2.2-fold with certain inhibitors. Conversely, CYP3A4 inducers may reduce Docetaxel exposure. Additionally, co-administration with Carbamazepine is associated with an increase in its own plasma concentrations.

Pharmacodynamic and Substance Interactions

The antibiotic components (Cefixime and Ceftazidime) may cause a documented fall in prothrombin activity or an increase in prothrombin times when used concurrently with Oral Anticoagulants (e.g., Warfarin). Furthermore, the use of antibacterial agents may result in a reduced therapeutic effect of Live Bacterial Vaccines. The alcohol content in the parenteral Docetaxel formulation may also produce effects on the central nervous system.

Population and Administration Notes

The product is formally contraindicated in patients with a history of severe hypersensitivity to the Docetaxel component or to other drugs formulated with Polysorbate 80. Renal Impairment leads to high and prolonged plasma concentrations of the cephalosporin components. The administration of food increases the time to maximal absorption of the oral Cefixime component.

Mechanism of Action

How Zytax Works on a Cellular Level

Zytax is an agent that acts by targeting the machinery involved in cell division and promoting cell death. Its mechanism is centered on two key cellular processes: stabilizing the cell's internal structure and triggering self-destruction. This results in a physiological consequence characterized by the interruption of cell proliferation in specific cell populations.

Stabilizing Microtubules to Halt Cell Division

This mechanism covers the compound's core molecular target: the tubulin protein that forms the cell's rigid internal tracks, known as microtubules. Zytax binds directly to these structures, preventing the physiological depolymerization and rearrangement of the structure. This stabilization causes a defect in the cell's ability to form a functional structure necessary for separation, which induces the arrest of the cell at the G2/M phase checkpoint of the replication cycle.

Promoting Programmed Cell Death (Apoptosis)

This downstream mechanism describes how the failure of cell division leads to the activation of intrinsic death pathways. The sustained arrest of the cell cycle acts as a critical signal that forces the cell to undergo apoptosis, or programmed cell death. This cascade is the final step in the drug's action, resulting in the elimination of the affected cell and a consequential net decrease in the count of cells that were susceptible to the mechanism.

Dosage and Administration Information

How Zytax is Used

Zytax is an integrated therapeutic agent that requires administration via two distinct routes and follows a split-frequency schedule based on its components—Cefixime, Ceftazidime, and Docetaxel.


Administration and Scheduling Protocol

Component and Route Standard Adult Dosing Regimen Frequency and Duration Pattern
Cefixime (Oral) Typically 400 mg per day. Once daily or in divided doses; short course, e.g., 7 to 14 days.
Ceftazidime (IV Infusion) 1 g to 2 g per administration. Divided doses (every 8 to 12 hours); short course.
Docetaxel (IV Infusion) 75 mg/ m^2 to 100 mg/ m^2 BSA. Cyclic use, typically once every 21 days (a 3-week course); long-term plan.

Procedural and Population Requirements

Dual Route Administration: The oral component (Cefixime) may be taken without regard to food. The intravenous components (Ceftazidime and Docetaxel) require specialized administration in a healthcare setting. The Docetaxel component necessitates dilution prior to infusion and is administered over a defined time, such as one hour.

Dose Adjustment: Modification of the Cefixime and Ceftazidime doses is required in patients with impaired renal function to account for slower clearance. Similarly, adjustments to the Docetaxel dose are required for patients with impaired hepatic function according to specified thresholds.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zytax

Evidence for Use in Managing Malignant Cellular Proliferation

The research record for the antineoplastic component (Docetaxel) was studied for conditions such as Metastatic Breast Cancer and Non-Small Cell Lung Cancer (NSCLC), primarily using large-scale Randomized Controlled Trials (RCTs). Researchers monitored specific long-term outcomes related to systemic or functional imbalance, including measurements of patient survival over several years (Overall Survival) and the length of time patients remained free from the progression of the disease (Progression-Free Survival).

For these conditions, studies monitored how tumors evolved in the observed populations, measuring the frequency and extent of tumor size reduction. Studies were designed to compare the antineoplastic component against other active treatments or standard care. Findings describe patterns observed in these studies, though findings were mixed when comparing different combination regimens against each other. Research explored the use of the component both as a first treatment and after the failure of other chemotherapy types.

Evidence for Use in Severe Systemic Infections

The research for the antibacterial components (Cefixime and Ceftazidime) was conducted using Randomized Controlled Trials and comprehensive Meta-Analyses. These studies focused on conditions associated with acute or disruptive episodes, such as Septicemia and other serious systemic infections. Research monitored outcomes reflecting daily functioning or activity level in acute settings, with a primary focus on short-term markers like patient survival (often tracked for 30 days) and the rate at which the absence of targeted bacteria was monitored in the system (microbiological eradication).

Studies compared these third-generation cephalosporins against other established antibiotics. Findings describe patterns observed during the acute treatment period. Findings describe patterns related to short-term changes, but the evidence base for the use of the two specific antibiotic components as a single, fixed-dose combination remains limited and relies on the known use of the individual agents within their class.

What is Still Uncertain About Zytax

Despite the extensive research on the individual components, several limitations in the combined evidence base exist. Comparative evidence is lacking for the specific, fixed-dose combination of the two cephalosporins against other modern, single-agent broad-spectrum antibiotics. Furthermore, there is limited information for long-term outcomes beyond the acute treatment phase for the antibacterial components.

Crucially, research is ongoing regarding any potential interactions between antineoplastic and antibacterial drugs, and the evidence base does not explicitly address the study findings when the full Zytax formulation (with all three components) is used concurrently over long periods. The results apply only to the populations studied and research does not determine whether an individual will respond similarly outside the defined parameters of the clinical trials.

Key Studies & References

  1. FDA DailyMed: Ceftazidime Indications and Overview
  2. Systemic Therapy for Breast Cancer (PDQ®): Evidence Review (Includes Docetaxel)
  3. Third- and Fourth-Generation Cephalosporins: Systematic Review and Meta-analysis on Effectiveness Against Carbapenem-Resistant Enterobacteriaceae (CRE)

Frequently Asked Questions (FAQ)

Common questions about Zytax (FAQ)


Q: Are there specific vitamins or supplements that should be avoided when taking Zytax?

Official information describes known interactions with compounds that affect certain liver enzymes (CYP3A4). This category may include some herbal remedies or supplements. Additionally, the antibiotic components of Zytax may reduce the therapeutic effect of certain live bacterial vaccines. Regulatory documentation recommends informing a healthcare professional about all concurrent supplements and remedies.

Q: Does Zytax affect sleep patterns?

Adverse reaction listings found in official documents for the components of Zytax include documented effects such as insomnia (difficulty sleeping) and fatigue (tiredness). Changes in sleep patterns are a documented adverse reaction that should be reported to the prescribing healthcare professional.

Q: Why does Zytax need a prescription?

Zytax is designated as a Prescription Only Medicine (POM) by regulatory agencies. This classification is used because the drug is complex, involves specialized administration for its intravenous components, and necessitates professional monitoring due to its potential for serious adverse effects.

Q: Does Zytax interact with common medications for high blood pressure?

The official product documentation outlines known interactions, including those with certain drug classes like Oral Anticoagulants (blood thinners). Official information suggests providing a complete list of all concurrent medications, including any used for high blood pressure, to the healthcare professional managing the treatment.

Q: How quickly can I expect Zytax to start having an effect?

Regulatory documents describe the drug's pharmacokinetic profile, which details how quickly the components are absorbed and reach their highest concentration in the body. The full therapeutic outcome is linked to the overall duration of the multi-component treatment plan, rather than a single dose.

Q: What is the longest period of time a person can use Zytax?

The duration of use is defined in the regulatory labeling based on the component. The antibiotic components are typically intended for a short course (e.g., 7 to 14 days). The chemotherapy component, Docetaxel, is part of a planned, cyclic treatment course, usually administered over a specified long-term plan.

Q: Does Zytax cause weight gain or weight loss?

Official adverse reaction listings include documented observations of changes in weight, reporting both instances of weight increase and weight decrease in clinical studies for the components of Zytax.

Q: Is it common to feel tired when first starting Zytax?

Fatigue and asthenia (a physical lack of energy) are frequently reported adverse reactions noted in the official documentation for the drug's components.

Q: What happens if I miss a scheduled dose of Zytax?

Official patient instructions typically include specific, non-directive guidance for managing a missed dose of the oral component (Cefixime). If an intravenous dose is missed, the patient's healthcare professional or clinical team manages the rescheduling of the specialized administration.

Q: Is Zytax considered a controlled substance by the government?

No. Regulatory agencies classify substances based on their potential for abuse. Zytax and its active components are not typically classified or scheduled as controlled substances by governmental bodies in the United States or the European Union.

Q: Do studies show Zytax is effective for long-term use?

Clinical trial results summarized in regulatory documents detail the observed efficacy over the full planned duration of the studies. This evidence supports the use of the drug in the multi-cycle, long-term treatment plans for which it is approved.

Q: Why do people sometimes say Zytax 'stops working' after a while?

Clinical data published in official research summaries may describe instances of diminished response or treatment resistance occurring in some patient populations over time. This observation relates to the biological characteristics of the condition being treated and is a known possibility addressed in the evidence.

Q: Can Zytax be used by individuals with mild liver issues?

Official labeling defines specific requirements for use based on liver function. The dose of the Docetaxel component must be adjusted or reduced according to official guidelines in patients with documented impaired liver function.

Q: Is there a generic version of Zytax available?

The availability of a generic version (a drug that is bioequivalent to the original) is public information. Regulatory agencies maintain official databases, such as the FDA's Orange Book, that document which bioequivalent drug products have been approved and are available.

Q: Is Zytax known to cause changes in mood or anxiety levels?

Yes, official adverse reaction data for the drug components list neurological and psychiatric effects, which may include documented changes in mood or levels of anxiety observed in clinical studies.

Q: Is Zytax a lifelong medication or is it typically used short-term?

Zytax is generally prescribed as a planned treatment course with a defined duration, rather than a lifelong medicine. The regimen includes short-term antibiotic components and cyclic, long-term administration for the chemotherapy component, according to a set plan.

Q: Can Zytax cause skin rashes or itching?

Official adverse reaction listings confirm that dermatological effects like skin rash and pruritus (itching) are explicitly listed as possible adverse reactions observed in clinical trials for the drug's components.

Q: Does Zytax affect the results of any common lab tests?

Yes, regulatory warnings describe documented interference with certain laboratory parameters. These may include changes in blood cell counts, liver function tests, or an increase in prothrombin times, which is why regular monitoring is required.

Q: What are the storage requirements for Zytax once the bottle is opened?

Official documents provide specific instructions regarding the recommended storage temperature and conditions (e.g., protection from light) for the components. This includes the maximum allowable duration of storage after the oral bottle is opened or after the intravenous components are prepared.

Q: Is Zytax known to cause dependency or withdrawal symptoms?

Official regulatory documents explicitly address the drug's potential for physical dependence, abuse, or the occurrence of withdrawal effects if the substance is relevant to these risks.

Q: Are there any dietary restrictions associated with Zytax use?

Official patient information describes known interactions, including a potential concern with certain foods or juices, such as grapefruit juice, that can impact the concentration of the Docetaxel component in the body. Other restrictions are generally outlined in the patient leaflet.

Q: Does using Zytax affect a person's fertility?

Official regulatory documentation contains a formal warning regarding the drug's potential impact on fertility and reproductive toxicity, based on preclinical data.

Q: How long does Zytax stay in your system after the last dose?

The elimination half-life (T1/2), which determines clearance, is formally documented in the pharmacokinetics section of the regulatory documents for each component. This is the scientific measure used to estimate the time required for the drug to be substantially eliminated from the body.

Q: Is it possible to be allergic to Zytax?

Yes. A history of severe hypersensitivity (allergic reaction) to the active components (Cefixime, Ceftazidime, Docetaxel) or to the excipient Polysorbate 80 is listed in the official documents as a formal contraindication (a reason the drug must not be used).

Q: What kind of studies were done to get Zytax approved?

Official labeling details the clinical evidence base used for approval. This includes the study design (e.g., randomized, controlled trials), the patient population enrolled, and the defined primary endpoints that were met to demonstrate the drug's efficacy.

Q: Are there any known interactions between Zytax and herbal remedies?

Regulatory interaction sections reference specific herbal agents like St. John's Wort that are known to affect the CYP3A4 enzyme system. This enzyme is responsible for clearing the Docetaxel component, meaning these agents could potentially alter the drug’s concentration in the body.

Q: What does the term 'contraindication' mean regarding Zytax?

A contraindication is a formal regulatory term defined in patient-facing documents. It means that the drug must not be used in a particular situation or by a certain patient group because the risk of causing harm is known to outweigh any potential benefit.

Q: Can Zytax be crushed or split if a person has trouble swallowing pills?

Regulatory instructions state that the tablet should not be modified by crushing or splitting unless explicitly authorized by the prescribing information. This is necessary to maintain the tablet's integrity and correct absorption characteristics.

Q: Is Zytax safe for women who are planning to become pregnant?

Regulatory documents categorize the potential risks during pregnancy and provide formal recommendations. Women of childbearing potential are advised that effective contraception should be used during treatment and for a specified time period after the last dose.

Q: Does the effectiveness of Zytax decrease over time?

Clinical trial data provides evidence of the drug's effectiveness throughout the duration of the study. This data tracks changes in the response rate or progression-free survival over the course of the approved treatment regimen.

Q: What should be done if I experience mild, non-serious side effects from Zytax?

Patient-facing regulatory information generally advises that for common, minor effects, you should observe your symptoms. Patients are advised by official information to notify their healthcare provider if any side effect becomes bothersome or persistent.

Q: Are there specific populations where Zytax has not been studied?

Official documentation identifies which subpopulations were not adequately included in the clinical trials, such as pediatric patients or individuals with certain end-stage organ failures. This leads to a lack of definitive data for those specific groups.

Q: How do doctors generally monitor a patient's progress while on Zytax?

Regulatory documents mandate specific monitoring procedures during treatment. These typically include regular checks of blood cell counts and tests of liver and kidney function to ensure safe continuation of the therapy.

Q: What is the source of the active ingredient in Zytax?

Official drug monographs describe the chemical structure and general synthesis of the active ingredients. This includes the semi-synthetic origin of the Docetaxel component and the cephalosporin structure of the antibiotic components.

Q: What is the difference between Zytax and a supplement?

Zytax is an approved prescription drug, meaning it has undergone rigorous testing and demonstrated efficacy and safety to the standards required by regulatory agencies. In contrast, dietary supplements are regulated as food products and do not require the same level of scientific proof for claims.

Q: Is Zytax known to be affected by grapefruit juice?

Official documents often explicitly mention that substances which inhibit the CYP3A4 enzyme system—such as grapefruit juice—may increase the concentration of the Docetaxel component in the blood due to reduced clearance.

Q: How does Zytax get eliminated from the body?

The regulatory documentation details the excretion pathways for the drug's components. Elimination occurs via a combination of the urine (primarily for the antibiotic components) and clearance through the liver (for the Docetaxel component).

Q: What should I tell a new healthcare provider about my Zytax use?

Patient-facing instructions recommend describing all current medications, history of allergies, and existing health conditions to any new healthcare provider to ensure continuity of care.

Q: Are there specific tests required before starting Zytax?

Yes, official documentation mandates pre-treatment screening tests before the initial dose. These are typically baseline assessments of blood cell counts and liver and kidney function to ensure the drug can be started appropriately.

Q: Can Zytax cause problems with vision or hearing?

Adverse reaction listings explicitly cover documented sensory effects for the drug components. This may include changes in vision (due to potential neurotoxicity) or events related to hearing (ototoxicity).

How should Zytax be stored and disposed of?

How to Store and Dispose of Zytax?

Official regulatory documents define strict rules for storing and disposing of Zytax, reflecting its complex composition. The medicine must be stored out of the reach and sight of children at all times.

Storage Conditions

  • Temperature and Light: Unreconstituted parenteral components must be stored at Controlled Room Temperature (20 C to 25 C) and actively protected from light. The oral powder component should be stored below 30 C.
  • Packaging: Keep the medicine in its original container, tightly closed, to prevent degradation.

Stability and Disposal

  • Stability: Reconstituted oral suspension must be discarded after 14 days (if refrigerated). Single-dose parenteral vials require immediate discarding of any unused portion after administration.
  • Disposal: Do not dispose of Zytax through household trash or wastewater. The cytotoxic component is classified as a hazardous drug and requires professionals to follow special handling procedures and local regulations for cytotoxic waste disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Zytax found in:

A-Z Index: